Literature DB >> 12707929

Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia.

D Mancama1, M J Arranz, S Landau, R Kerwin.   

Abstract

The involvement of specific pathways mediated through muscarinic receptor activity has been widely implicated in schizophrenia. Extensive pharmacological evidence supports the systems role in mediating antipsychotic drug efficacy, while mounting physiological evidence demonstrates the presence of significant alterations to normal muscarinic receptor integrity in the disorder. The mechanisms that facilitate the systems involvement and their magnitude, however, remain poorly understood. We have proposed that alterations to normal muscarinic receptor expression exist in schizophrenia, and that these significantly influence the physiological changes often reported for the system amongst patients. In this study, we investigate this potential, and have selected to examine the muscarinic 1 receptor, which constitutes a major target for antipsychotic action and plays a conspicuous role in those regions central to the disorders pathophysiology. Using relative gene quantification, we measured post-mortem levels of steady-state cortical muscarinic 1 receptor cDNA in patients (N = 20) and unaffected controls (N = 20), and examined group differences in expression levels. Commensurate with our hypothesis, we observed significant reductions in muscarinic 1 receptor cDNA in our patient sample (F(1,37) = 4.73, P = 0.036) and have estimated this to constitute a 28% decrease compared to the control subjects (95% CI from 2 to 47%). These results provide evidence in support of altered muscarinic 1 receptor expression in schizophrenia, though further work is needed to corroborate these findings. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12707929     DOI: 10.1002/ajmg.b.20020

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  22 in total

1.  Discovery of potential antipsychotic agents possessing pro-cognitive properties.

Authors:  Jelveh Lameh; Krista McFarland; Jorgen Ohlsson; Fredrik Ek; Fabrice Piu; Ethan S Burstein; Ali Tabatabaei; Roger Olsson; Stefania Risso Bradley; Douglas W Bonhaus
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-11-15       Impact factor: 3.000

Review 2.  Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.

Authors:  Carrie K Jones; Nellie Byun; Michael Bubser
Journal:  Neuropsychopharmacology       Date:  2011-09-28       Impact factor: 7.853

Review 3.  Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions.

Authors:  Richard S Jope; Myoung-Sun Roh
Journal:  Curr Drug Targets       Date:  2006-11       Impact factor: 3.465

4.  Changes in BQCA Allosteric Modulation of [(3)H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.

Authors:  Brian Dean; Shaun Hopper; P Jeffrey Conn; Elizabeth Scarr
Journal:  Neuropsychopharmacology       Date:  2015-10-29       Impact factor: 7.853

Review 5.  Sexually selected traits: a fundamental framework for studies on behavioral epigenetics.

Authors:  Eldin Jašarević; David C Geary; Cheryl S Rosenfeld
Journal:  ILAR J       Date:  2012

6.  Brain region-specific alterations in the gene expression of cytokines, immune cell markers and cholinergic system components during peripheral endotoxin-induced inflammation.

Authors:  Harold A Silverman; Meghan Dancho; Angelique Regnier-Golanov; Mansoor Nasim; Mahendar Ochani; Peder S Olofsson; Mohamed Ahmed; Edmund J Miller; Sangeeta S Chavan; Eugene Golanov; Christine N Metz; Kevin J Tracey; Valentin A Pavlov
Journal:  Mol Med       Date:  2015-03-11       Impact factor: 6.354

Review 7.  Cholinergic contributions to the cognitive symptoms of schizophrenia and the viability of cholinergic treatments.

Authors:  Martin Sarter; Cindy Lustig; Stephan F Taylor
Journal:  Neuropharmacology       Date:  2010-12-13       Impact factor: 5.250

Review 8.  G protein-coupled receptors in major psychiatric disorders.

Authors:  Lisa A Catapano; Husseini K Manji
Journal:  Biochim Biophys Acta       Date:  2006-10-03

9.  Modulation of prepulse inhibition through both M(1) and M (4) muscarinic receptors in mice.

Authors:  Morgane Thomsen; Jürgen Wess; Brian S Fulton; Anders Fink-Jensen; S Barak Caine
Journal:  Psychopharmacology (Berl)       Date:  2009-12-15       Impact factor: 4.530

Review 10.  A neurocognitive animal model dissociating between acute illness and remission periods of schizophrenia.

Authors:  Martin Sarter; Vicente Martinez; Rouba Kozak
Journal:  Psychopharmacology (Berl)       Date:  2008-07-10       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.